QNRX · Quoin Pharmaceuticals Ltd.
AI read · Good for QNRX
The AI's read
The status can help Quoin get scientific advice, lower fees, and access European grants. Those benefits may help as it prepares to study QRX003. But the treatment is not approved, and the company says its first formal study is still ahead. The possible 10 years of market exclusivity depends on approval, so this is encouraging progress, not proof the treatment will reach patients.